 |
|
In Utero Hematopoietic Stem Cell TransplantationA Status Report
Alan W. Flake, MD;
Esmail D. Zanjani, PhD
JAMA. 1997;278(11):932-937.
Abstract
| |
In utero hematopoietic stem cell transplantation is currently in its early stage of development, but it holds considerable promise as a therapeutic approach for the treatment of a large number of congenital hematologic diseases. Experimental evidence supports the concept of the early gestational fetus as a favorable recipient for cellular therapy. Unique aspects of normal hematologic and immunologic ontogeny allow engraftment and long-term persistence of transplanted hematopoietic stem cells without the requirement for myeloablation or immunosuppression. To date, 21 in utero transplants have been reported. Success has been limited to 4 fetuses, all with immunodeficiency disorders. Despite this limited evidence of clinical efficacy, interest in stem cell transplantation has been gaining momentum, and clinical application is likely to increase. Parallel advances in prenatal diagnosis, fetal intervention, and hematopoietic stem cell technology have removed many of the practical, technical, and ethical obstacles to clinical application. This progress has been accompanied by an increase in the number of centers with both the stated interest and perceived expertise to develop clinical programs. However, there is currently limited consensus among investigators on many important issues, such as the mode or timing of in utero transplantation, the ideal source or dose of donor cells, estimation of maternal and fetal risks, appropriate candidate diseases for treatment, and important ethical considerations in counseling and therapy.
Author Affiliations
From the Department of Surgery and the Center for Fetal Diagnosis and Therapy, Children's Hospital of Philadelphia, University of Pennsylvania (Dr Flake), and the Department of Medicine, Veterans Affairs Medical Center, University of Nevada, Reno (Dr Zanjani).
Footnotes
Reprints: Alan W. Flake, MD, Department of Surgery, Children's Hospital of Philadelphia, Abramson Pediatric Research Center, Room 1102D, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104 (email: flake@email.chop.edu).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Allogenic fetal liver cells have a distinct competitive engraftment advantage over adult bone marrow cells when infused into fetal as compared with adult severe combined immunodeficient recipients
Taylor et al.
Blood 2002;99:1870-1872.
ABSTRACT
| FULL TEXT
Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival
Myers et al.
Blood 2002;99:872-878.
ABSTRACT
| FULL TEXT
Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation
Almeida-Porada et al.
Blood 2000;95:3620-3627.
ABSTRACT
| FULL TEXT
Stem cell technology
Fontes and Thomson
BMJ 1999;319:1308-1308.
FULL TEXT
In Utero Hematopoietic Stem Cell Transplantation: Ontogenic Opportunities and Biologic Barriers
Flake and Zanjani
Blood 1999;94:2179-2191.
FULL TEXT
Prospects for in Utero Human Gene Therapy
Zanjani and Anderson
Science 1999;285:2084-2088.
ABSTRACT
| FULL TEXT
Treatment of Severe Combined Immunodeficiency
Flake et al.
NEJM 1999;341:291-292.
FULL TEXT
|
